# US 2010/0063080 A1 · CXCR2 inhibitors

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2010/0063080 A1
- Document ID: US20100063080A1
- Status: Published application
- Kind: A1
- Application number: 12/514,740
- Filed: 2007-11-21
- Published: 2010-03-11
- Earliest claimed: 2006-11-23
- Inventors: Neil John Press; Peter Hunt; David Porter; Diana Janus
- Web page: https://patentgrep.com/patent/US20100063080A1

## CPC

- C07D 239/56: One oxygen atom and one sulfur atom
- A61P 1/04: for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A61P 1/16: for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
- A61P 1/18: for pancreatic disorders, e.g. pancreatic enzymes
- A61P 9/00: Drugs for disorders of the cardiovascular system
- A61P 9/10: for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- A61P 11/00: Drugs for disorders of the respiratory system
- A61P 11/02: Nasal agents, e.g. decongestants
- A61P 11/06: Antiasthmatics
- A61P 13/08: of the prostate
- A61P 13/12: of the kidneys
- A61P 15/00: Drugs for genital or sexual disorders (for disorders of sex hormones A61P5/24); Contraceptives
- A61P 17/00: Drugs for dermatological disorders
- A61P 17/06: Antipsoriatics
- A61P 19/00: Drugs for skeletal disorders
- A61P 19/02: for joint disorders, e.g. arthritis, arthrosis
- A61P 25/00: Drugs for disorders of the nervous system
- A61P 25/28: for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A61P 27/16: Otologicals
- A61P 29/00: Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A61P 31/04: Antibacterial agents
- A61P 31/12: Antivirals
- A61P 31/18: for HIV
- A61P 35/00: Antineoplastic agents
- A61P 37/04: Immunostimulants
- A61P 37/06: Immunosuppressants, e.g. drugs for graft rejection
- A61P 37/08: Antiallergic agents (antiasthmatic agents A61P11/06; ophthalmic antiallergics A61P27/14)
- A61P 43/00: Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C07D 401/04: directly linked by a ring-member-to-ring-member bond
- C07D 405/04: directly linked by a ring-member-to-ring-member bond
- C07D 409/04: directly linked by a ring-member-to-ring-member bond
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

The present invention relates to compounds of formula (I) and the use of these compounds as pharmaceuticals, e.g. in preventing or treating a CXCR2 receptor mediated condition or disease.

## Claims

### Claim 1

A method for the prevention or treatment of a CXCR2 receptor mediated condition or disease comprising administering an effective amount of at least one compound of formula
wherein
R1 is (C6-18)aryl or (C6-18)aryl(C1-4)alkyl, unsubstituted or one- or morefold substituted by (C1-4)alkyl, C1-4)alkoxy, hydroxy, halogen,
R2 is
(C1-8)alkyl, halo(C1-8)alkyl, amino, substituted amino,
(C6-18)aryl, unsubstituted or one- or morefold substituted by (C1-4)alkyl, C1-4)alkoxy, hydroxy or halogen,
(C6-18)aryl(C1-8)alkyl, unsubstituted or one- or morefold substituted,
heterocyclyl or heterocyclyl(C1-8)alkyl, wherein heterocyclyl has 5 to 6 ring members and 1 to 4 heteroatoms selected from N, O, S, unsubstituted or one- or morefold substituted,
(C3-8)cycloalkyl or (C3-8)cycloalkyl(C1-8)alkyl, unsubstituted or, one- or morefold substituted,
or a pharmaceutically acceptable salt or solvate thereof.

### Claim 2 (depends on 1)

The method of claim 1, wherein
R1 is phenyl or phenyl(C1-2)alkyl, unsubstituted or one- or morefold substituted by (C1-4)alkyl, C1-4)alkoxy, hydroxy, halogen,
R2 is
(C1-4)alkyl, halo(C1-4)alkyl, amino and substituted amino,
unsubstituted phenyl or phenyl substituted by (C1-4)alkyl, C1-4)alkoxy, hydroxy, halogen, heterocyclyl,
phenyl(C1-4)alkyl or phenyl(C1-4)alkyl, unsubstituted or one- or twofold substituted,
heterocyclyl or heterocyclyl(C1-4)alkyl, wherein heterocyclyl has 5 to 6 ring members and 1 to 4 heteroatoms selected from N, O, S, unsubstituted or one- or twofold substituted,
(C3-6)cycloalkyl or (C3-8)cycloalkyl(C1-4)alkyl, unsubstituted or one- or twofold substituted.

### Claim 3 (depends on 1)

The method of claim 1, wherein
R1 is unsubstituted benzyl or benzyl twofold substituted by fluoro,
R2 is
methyl, sec.butyl, tert.butyl, trifluoromethyl, amino substituted by 2-methylfuran-5-yl-1-propyl,
unsubstituted phenyl or phenyl one or twofold substituted by methyl, methoxy, iso-propoxy, hydroxy, chloro or thienyl,
1-phenyl-ethyl,
furanyl, 5-methyl-furan-2-yl-2-propyl, thienyl or pyridinyl,
unsubstituted cyclopropylmethyl,
unsubstituted cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl
cyclopropyl onefold substituted by ethoxycarbonyl, hydroxymethyl, hydroxycarbonyl, or a group of formula NR3R4—C═O—, wherein
R3 and R4 independently are hydrogen, methyl, ethyl, 2-methyl-allyl, cyclopropylmethyl, methoxymethyl, ethoxycarbonylmethyl, hydroxymethyl, hydroxycarbonylmethyl, phenetyl, benzyl, benzyl substituted by methoxy, pyridin-3-yl-methyl, furan-2-yl-methyl, or
R3 and R4 together form a 5 membered alicyclic ring system substituted by ethyl, a 6 membered alicyclic ring substituted by hydroxy, a 6 membered alicyclic ring having 0 as a further heteroatom, a 6 membered alicyclic ring having N as a further heteroatom which further N is substituted by tert.-butyloxycarbonyl.

### Claim 4 (depends on 1)

The method of claim 1, wherein the compound of formula (I) is administered in combination with at least one second drug substance.

### Claim 5 (depends on 1)

The method of claim 1, wherein the CXCR2 receptor mediated condition or disease is an inflammatory or allergic condition or disease.

### Claim 6

A compound selected from the group consisting of
2-(2,3-Difluoro-benzylsulfanyl)-4-hydroxy-6-(4-methoxy-phenyl)-pyrimidine-5-carbonitrile,
4-(3,4-Dichlorophenyl)-2-(2,3-difluorobenzylsulfanyl-6-hydroxy-pyrimidine-5-carbonitrile,
2-(2,3-Difluorobenzylsulfanyl)-4-hydroxy-6-(4-hydroxyphenyl)-pyrimidine-5-carbonitrile,
4-cyclopropyl-2-(2,3-difluorobenzylsulfanyl-6-hydroxypyrimidine-5-carbonitrile,
2-(2,3-Difluoro-benzylsulfanyl)-4-hydroxy-6-phenyl-pyrimidine-5-carbonitrile,
4-(4-Chlorophenyl)-2-(2,3-difluoro-benzyl-sulfanyl)-6-hydroxy-6-phenyl-pyrimidine-5-carbonitrile,
4-(4-Methylphenyl)-2-(2,3-difluoro-benzylsulfanyl)-6-hydroxy-6-phenyl-pyrimidine-5-carbonitrile,
2-(2,3-Difluoro-benzylsulfanyl)-4-furan-2-yl-6-hydroxy-pyrimidine-5-carbonitrile,
2-(2,3-Difluoro-benzylsulfanyl)-4-hydroxy-6-pyridin-3-yl-pyrimidine-5-carbonitrile,
2-(2,3-Difluoro-benzylsulfanyl)-4-hydroxy-6-pyridin-4-yl-pyrimidine-5-carbonitrile,
2-(2,3-Difluoro-benzylsulfanyl)-4-hydroxy-6-(4-thiophen-2-yl-phenyl)-pyrimidine-5-carbonitrile,
2-(2,3-Difluoro-benzylsulfanyl)-4-hydroxy-6-m-tolyl-pyrimidine-5-carbonitrile,
2-(2,3-Difluoro-benzylsulfanyl)-4-furan-3-yl-6-hydroxy-pyrimidine-5-carbonitrile,
2-(2,3-Difluoro-benzylsulfanyl)-4-hydroxy-6-(4-isopropoxy-phenyl)-pyrimidine-5-carbonitrile,
4-(4-tert-Butyl-phenyl)-2-(2,3-difluoro-benzylsulfanyl)-6-hydroxy-pyrimidine-5-carbonitrile,
2-(2,3-Difluoro-benzylsulfanyl)-4-(3,4-dimethyl-phenyl)-6-hydroxy-pyrimidine-5-carbonitrile,
4-Cyclopentyl-2-(2,3-difluoro-benzylsulfanyl)-6-hydroxy-pyrimidine-5-carbonitrile,
4-Cyclopropyl-2-(2,3-difluoro-benzylsulfanyl)-6-hydroxy-pyrimidine-5-carbonitrile,
2-(2,3-Difluoro-benzylsulfanyl)-4-hydroxy-6-(4-methoxy-3-methyl-phenyl)-pyrimidine-5-carbonitrile,
4-Cyclobutyl-2-(2,3-difluoro-benzylsulfanyl)-6-hydroxy-pyrimidine-5-carbonitrile,
2-(2,3-Difluoro-benzylsulfanyl)-4-hydroxy-6-isopropyl-pyrimidine-5-carbonitrile,
4-Cyclohexyl-2-(2,3-difluoro-benzylsulfanyl)-6-hydroxy-pyrimidine-5-carbonitrile,
2-[5-Cyano-2-(2,3-difluoro-benzylsulfanyl)-6-hydroxy-pyrimidin-4-yl]-cyclopropanecarboxylic acid ethyl ester,
2-(2,3-Difluoro-benzylsulfanyl)-4-ethyl-6-hydroxy-pyrimidine-5-carbonitrile,
4-sec-Butyl-2-(2,3-difluoro benzyl sulfanyl)-6-hydroxy-pyrimidine-5-carbonitrile,
4-tert-Butyl-2-(2,3-difluoro-benzylsulfanyl)-6-hydroxy-pyrimidine-5-carbonitrile,
2-(2,3-Difluoro-benzylsulfanyl)-4-hydroxy-6-(1-phenyl-ethyl)-pyrimidine-5-carbonitrile,
2-(2,3-Difluoro-benzylsulfanyl)-4-hydroxy-6-trifluoromethyl-pyrimidine-5-carbonitrile,
2-(2,3-Difluoro-benzylsulfanyl)-4-hydroxy-6-methyl-pyrimidine-5-carbonitrile,
4-sec-Butyl-2-(2,3-difluoro-benzyl sulfanyl)-6-hydroxy pyrimidine-5-carbonitrile single enantiomer E1,
4-sec-Butyl-2-(2,3-difluoro-benzyl sulfanyl)-6-hydroxy pyrimidine-5-carbonitrile single enantiomer E2,
2-(2,3-Difluoro-benzylsulfanyl)-4-hydroxy-6-(3-hydroxy-phenyl)-pyrimidine-5-carbonitrile-4-sec-Butyl-2-(2,3-difluoro-benzyl sulfanyl)-6-hydroxy pyrimidine-5-carbonitrile,
2-(2,3-Difluoro-benzylsulfanyl)-4-hydroxy-6-(1-phenyl-ethyl)-pyrimidine-5-carbonitrile,
4-Cyclopropylmethyl-2-(2,3-difluoro-benzylsulfanyl)-6 hydroxy-pyrimidine-5-carbonitrile,
Trans-2-[5-Cyano-2-(2,3-difluoro-benzylsulfanyl)-6 hydroxy-pyrimidin-4-yl]cyclopropane carboxylic acid,
(1R,2R)-2-[5-Cyano-2-(2,3-difluoro-benzylsulfanyl)-6 hydroxy-pyrimidin-4-yl]cyclopropane carboxylic acid,
(1R,2R)-2-[5-Cyano-2-(2,3-difluoro-benzylsulfanyl)-6 hydroxy-pyrimidin-4-yl]cyclopropane carboxylic acid,
Trans-2-(2,3-Difluoro-benzylsulfanyl)-4-hydroxy-6-(2-hydroxymethyl-cyclopropyl)-pyrimidine-5-carbonitrile,
Trans-2-[5-Cyano-2-(2,3-difluoro-benzyl sulfanyl)-6-hydroxy-pyrimidin-4-yl]cyclopropane carboxylic acid ethyl-(2-methyl-allyl)-amide,
2-[5-Cyano-2-(2,3-difluoro-benzylsulfanyl)-6-hydroxy-pyrimidin-4-yl]-cyclopropane carboxylic acid ethyl-methyl-amide,
2-[5-Cyano-2-(2,3-difluoro-benzylsulfanyl)-6-hydroxy-pyrimidin-4-yl]-cyclopropane carboxylic acid cyclopropyl methyl-amide,
2-(2,3-Difluoro-benzylsulfanyl)-4-[2-(2-ethyl-pyrrolidine-1carbonyl)-cyclopropyl]-6-hydroxypyrimidine-5-carbonitrile,
2-[5-Cyano-2-(2,3-difluoro-benzylsulfanyl)-6-hydroxy-pyrimidin-4-yl]-cyclopropane carboxylic acid (1-methoxymethyl-propyl)-amide,
2-[5-Cyano-2-(2,3-difluoro-benzylsulfanyl)-6-hydroxy-pyrimidin-4-yl]-cyclopropane carboxylic acid phenethyl-amide,
2-[5-Cyano-2-(2,3-difluoro-benzylsulfanyl)-6-hydroxy-pyrimidin-4-yl]-cyclopropane carboxylic acid 2-methoxy-benzylamide,
2-(2,3-Difluoro-benzylsulfanyl)-4-hydroxy-6-[2-(3-hydroxy-piperidine-1-carbonyl)cyclopropyl]-pyrimidine-5-carbonitrile,
2-[5-Cyano-2-(2,3-difluoro-benzylsulfanyl)-6-hydroxy-pyrimidin-4-yl]-cyclopropane carboxylic acid (pyridin-3-ylmethyl)-amide,
Trans-({2-[5-Cyano-2-(2,3-difluoro-benzylsulfanyl)-6-hydroxy-pyrimidin-4-yl]-cyclopropane carbonyl}-amino)-acetic acid ethyl ester,
2-(2,3-Difluoro-benzylsulfanyl)-4-hydroxy-6-[2-(morpholine-4-carbonyl)-cyclopropyl]pyrimidine-5-carbonitrile,
2-[5-Cyano-2-(2,3-difluoro-benzylsulfanyl)-6-hydroxy-pyrimidin-4-yl]-cyclopropane carboxylic acid (furan-2-ylmethyl)-amide,
2-[5-Cyano-2-(2,3-difluoro-benzylsulfanyl)-6-hydroxy-pyrimidin-4-yl]-cyclopropane carboxylic acid amide,
Trans-4-{2-[5-Cyano-2-(2,3-difluoro-benzylsulfanyl)-6-hydroxy-pyrimidin-4-yl]-cyclopropane carbonyl}-piperazine-1-carboxylic acid tert-butyl ester,
Trans-({2-[5-Cyano-2-(2,3-difluoro-benzylsulfanyl)-6-hydroxy-pyrimidin-4-yl]-cyclopropane carbonyl}-amino)-acetic acid,
2-(2,3-Difluoro-benzylsulfanyl)-4-hydroxy-6-[(R)-2-(5-methyl-furan-2-yl)-propyl]-pyrimidine-5-carbonitrile,
(1S,2S)-2-(2,3-Difluoro-benzylsulfanyl)-4-hydroxy-6-(2-hydroxymethyl-cyclopropyl)-pyrimidine-5-carbonitrile,
2-(2,3-Difluoro-benzylsulfanyl)-4-hydroxy-6-[(R)-1-(5-methyl-furan-2-yl)-propylamino]-pyrimidine-5-carbonitrile and
(1R,2R)-2-(2,3-Difluoro-benzylsulfanyl)-4-hydroxy-6-(2-hydroxymethyl-cyclopropyl)-pyrimidine-5-carbonitrile.

### Claim 7

(canceled)

### Claim 8 (depends on 6)

A pharmaceutical composition comprising a compound of claim 6 together with at least: one pharmaceutically acceptable excipient.

### Claim 9 (depends on 6)

A method for the prevention or treatment of a CXCR2 receptor mediated condition or disease comprising administering an effective amount of at least one compound of claim 6 to a subject in need of such treatment.

### Claim 10 (depends on 9)

A method of claim 9 wherein the condition or disease is an inflammatory or allergic condition, particularly an inflammatory or obstructive airway disease.

### Claim 11 (depends on 5)

A method of claim 5 wherein the condition or disease is an inflammatory or allergic condition, particularly an inflammatory or obstructive airway disease.
